Rat pyelonephritis model suitable for primary or secondary screening.
A rat Proteus and Escherichia pyelonephritis model is described in which (i) reproducible chronic infections are achieved and (ii) the efficacy of clinically effective agents is reliably demonstrable with five rats in 17 days. It can serve as a primary screen in which one technician can evaluate 180 compounds per month with 900 rats. The manner of inoculation will inherently allow the study of and distinction between metabolism which is peculiar to infection and that which is characteristic of trauma and healing in general for the elucidation of chemical correlations with effective therapy.
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D008297:Male; D009268:Nalidixic Acid / Q000627:therapeutic use; D009582:Nitrofurantoin / Q000627:therapeutic use; D011512:Proteus Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013444:Sulfisoxazole / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D005839:Gentamicins; D009268:Nalidixic Acid; D013444:Sulfisoxazole; D000667:Ampicillin; D009582:Nitrofurantoin; D013420:Sulfamethoxazole